30results about How to "Definite inhibitory effect" patented technology

The invention discloses a method for preparing for tumour formingblood vessel peculiarity binding polypeptide and the admixture protein of human-5. The tumour formingblood vessel peculiarity binding polypeptid-CNGRCVSGCAGRC can separately combine with the tumour formingblood vessel endothelium cell surface high effect expressed aminopeptidase N (CD13). It establishes tumour formingblood vessel peculiarity binding polypeptide and the admixture protein of human-5 and obtains the high effect express in bacillus coli. It also discloses a method for preparing for human Tum-5. The Tum-5 is formed by the 54-132 bits amino acid near the N end of the Tumstatin, which is the function structure area of the Tumstatin anti-vascularization.

A method for preparing 13-docosenamide by fermenting a marine bacillus amyloliquefaciens BMF01 bacterial strain comprises the following steps: fermentation of the BMF01 bacterial strain and preparation of fermentation broth thereof, acid precipitation of the fermented broth of the BMF01 bacterial strain and methanol extraction, silica gel column chromatography of BMF01 bacterial strain fermentation broth methanol extract, Sephadex LH-20 column chromatography, then the absorption peak of MD-4 components appear at 11.5 min, and is identified to be a structure of the compound 13-docosenamide. The invention also relates to a method for preparing ester compounds from marine bacillus amyloliquefaciens BMF01. The method of the invention produces the 13-docosenamide and ester compounds having the application of inhibiting root rot of wheat. For the first time, five kinds of compounds with bacteriostatic action are prepared on the basis of BMF01 strain. The method has the advantages of simple method and high operability.

The invention discloses a bacteriostatic and antiviral preparation taking kidney bean phytohemagglutinin as a major ingredient, and belongs to the technical field of medicines. The bacteriostatic andantiviral preparation consists of the following active components according to relative parts by weight: 0.1-1.0 part of the kidney bean phytohemagglutinin, 0.2-2.0 parts of one or two of stachyose and raffinose as well as one or more of the following active components: 0.1-0.5 part of povidone iodine, 0.1-0.3 part of polyhexylene biguanidine and 0.1-0.5 part of chlorhexidine; and in addition, a thickening agent, which is hydroxyethyl cellulose, is required. The bacteriostatic and antiviral preparation provided by the invention is concrete in components, and is capable of achieving quantitative control and guaranteeing the consistency and stability of overall quality; a concrete inhibitory effect can be achieved on bacteria, fungi and viruses; therefore, the bacteriostatic and antiviral preparation is relatively broad in antibacterial and antiviral ranges; and the product (the bacteriostatic and antiviral preparation), which is required to be preserved at low temperature, is long in preservation duration and convenient to use.

The invention provides an application of macleyine alkaloid and its pharmaceutically acceptable salt, a salvation object, a polycrystalline object, an enantiomer or racemic mixture salt, a polycrystalline object, an optical isomer, a racemate , corydalis tuber containing macleyine alkaloid and its extract product, corydalis amabilis and its extract product, and macleaya cordata and its extract product in preparation of medicine for inhibiting P-gp. The invention provides an application of macleyine alkaloid and its pharmaceutically acceptable salt, the salvation object, the polycrystalline object, the enantiomer or racemic mixture salt, the polycrystalline object, the optical isomer, the racemate , corydalis tuber containing macleyine alkaloid and its extract product, corydalis amabilis and its extract product, and macleaya cordata and its extract product in preparation of medicine for auxiliary treatment of tumour. The auxiliary treatment of tumour is capable of reversing tumour multidrug resistance relative to high expression of P-gp, and is cooperated for synergizing antitumor drugs.

The invention relates to the application of papaya saponin in the preparation of preparations for treating acne, and belongs to the technical field of biomedicine. The present invention uses the self-made saponins of papaya, and observes in vitro experiments with liquid micro-dilution method, and the experiment proves that total saponins of papaya and saponins Ⅰ, Ⅱ, Ⅵ, and Ⅶ are effective against Propionibacterium acnes, Staphylococcus epidermidis and aureus in vitro. Staphylococcus has definite inhibitory effect and is used in the preparation of acne treatment preparations. The beneficial effects of the present invention are: the addition of plant-extracted papaya saponins to acne preparations not only has a definite inhibitory effect on Propionibacterium acnes, Staphylococcus epidermidis and Staphylococcus aureus, but also reduces the drug resistance and Irritation, providing safety of the preparation.

The invention discloses a preparation method of an antibiotic-crosslinked specific demineralized extracellular matrix scaffold, and belongs to the technical field of bone infection treatment. The invention discloses the preparation method of the antibiotic-crosslinked specific demineralized extracellular matrix scaffold, which comprises the following steps of by using a specific demineralized and decellularized cancellous bone extracellular matrix scaffold (SDECM) as a substrate, carrying out compound drug loading on the substrate and the antibiotics in two forms of electrostatic adsorption and chemical crosslinking, releasing antibiotics in two modes of rapid pH response and accompanying material degradation in an acid environment, and adopting the antibiotics for resisting infection and promoting repair through SDECM, so that the pH-sensitive release drug in the early acidic environment of infection is rapidly sterilized, the drug is slowly released in the middle-late physiological environment for continuous sterilization, the treatment effect of permanent sterilization capability and prevention of infection recurrence is still achieved in the absence of infection, and a new thought and a new tool are provided for antibacterial and repair treatment of bone infection.

The invention discloses an application of sanguinarine to restraining growth of staphylococcus lugdunensis. The sanguinarine has better in vitro destroying effects on medicine-resistant staphylococcuslugdunensis and can restrain the growth of the medicine-resistant staphylococcus lugdunensis, the minimum bactericidal concentration is 30 [mu]g/mL, and the minimal inhibitory concentration is 15[mu]g/mL. The invention provides the restraining effects of the sanguinarine on the staphylococcus lugdunensis, and the sanguinarine has high application value in the field of pharmaceuticals and the like.

The invention discloses application of luteolin in inhibition of growth of multi-drug-resistant providencia rettgeri. According to the invention, because the luteolin has a good in-vitro killing effect on multi-drug-resistant providencia rettgeri, the growth of the multi-drug-resistant providencia rettgeri can be inhibited; and the minimum bactericidal concentration is 30 to 250 microgram/mL and the minimum bacteriostatic concentration is 15 to 125 microgram/mL. The luteolin has an inhibiting effect on the multi-drug-resistant providencia rettgeri and thus has the great application value in the fields of medicines and the like.

The invention discloses an application of sanguinarine in inhibiting the growth of streptococcus pneumonia, according to the fact that the sanguinarine has a good in-vitro killing effect on streptococcus pneumonia, the sanguinarine can inhibit the growth of streptococcus pneumonia, the minimum bactericidal concentration is 31.2 mu g/mL, and the minimum inhibitory concentration is 15.6 mu g/mL. Thesanguinarine provided by the invention has an inhibition effect on pneumonia streptococcus, and has a wide application value in the fields of medicines and the like.

The invention discloses a palmatine hydrochloride-aspirin supramolecular compound as well as a preparation method and application thereof, and belongs to the technical field of medicine crystallization. The structural unit of the pharmaceutical co-crystal comprises palmatine hydrochloride molecules, aspirin molecules and water molecules, the molar ratio of the palmatine hydrochloride molecules to the aspirin molecules to the water molecules is 1: 1: 1, and the molecular formula of the pharmaceutical co-crystal is [C21H22ClNO3]. [C9H8O4]. H2O. The palmatine hydrochloride-aspirin supramolecular compound is prepared by mixing a palmatine hydrochloride hydrate and aspirin in a solvent according to a molar ratio of 1: 1 and carrying out spray drying, evaporation or suspension stirring and other processes, the preparation method is green and efficient, and the supramolecular compound is high in light stability, wet stability and thermal stability and weak in hygroscopicity, and can be used for preparing the palmatine hydrochloride-aspirin supramolecular compound. The compound has good human colorectal cancer cell inhibition activity, and can be used as an active component for preparing a pharmaceutical composition or a health care product for treating or preventing colorectal cancer.

The invention discloses application of chelerythrine in inhibiting the growth of multi-drug resistant providencia rettgeri. Chelerythrine has a good in-vitro killing effect, can inhibit the growth ofmulti-drug resistant providencia rettgeri, also a minimum bactericidal concentration is 20-250microg/mL, and a minimal inhibitory concentration is 10-125microg/mL. The invention puts forward the inhibition effect of chelerythrine on the multi-drug resistant providencia rettgeri, and has wide application value in medicine and other fields.